within Pharmacolibrary.Drugs.ATC.L;

model L01XK03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.36,
    Cl             = 0.255,
    adminDuration  = 600,
    adminMass      = 0.6,
    adminCount     = 1,
    Vd             = 0.113,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0082,
    Tlag           = 60.0
  );

  annotation(Documentation(
    info ="<html><body><p>Rucaparib is an oral poly (ADP-ribose) polymerase (PARP) inhibitor approved for the treatment of certain types of ovarian and prostate cancer. It is used especially in patients with BRCA mutations or deficiencies in homologous recombination repair. Rucaparib is currently approved and in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adults (cancer patients), following multiple oral doses of 600 mg twice daily.</p><h4>References</h4><ol><li><p>Liao, M, et al., &amp; Xiao, JJ (2022). Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib. <i>Clinical pharmacokinetics</i> 61(11) 1477–1493. DOI:<a href=&quot;https://doi.org/10.1007/s40262-022-01157-8&quot;>10.1007/s40262-022-01157-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36107395/&quot;>https://pubmed.ncbi.nlm.nih.gov/36107395</a></p></li><li><p>Green, ML, et al., &amp; Xiao, JJ (2022). Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors. <i>Cancer chemotherapy and pharmacology</i> 89(5) 671–682. DOI:<a href=&quot;https://doi.org/10.1007/s00280-022-04413-7&quot;>10.1007/s00280-022-04413-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35397664/&quot;>https://pubmed.ncbi.nlm.nih.gov/35397664</a></p></li><li><p>Grechko, N, et al., &amp; Xiao, J (2021). Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment. <i>Cancer chemotherapy and pharmacology</i> 88(2) 259–270. DOI:<a href=&quot;https://doi.org/10.1007/s00280-021-04278-2&quot;>10.1007/s00280-021-04278-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33909097/&quot;>https://pubmed.ncbi.nlm.nih.gov/33909097</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01XK03;
